Insider Transactions in Q1 2022 at Zentalis Pharmaceuticals, Inc. (ZNTL)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 21
2022
|
Kevin D. Bunker Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
10,000
-3.39%
|
$490,000
$49.11 P/Share
|
|
Mar 15
2022
|
Cam Gallagher President, Interim CFO |
SELL
Open market or private sale
|
Direct |
10,000
-0.89%
|
$420,000
$42.31 P/Share
|
|
Mar 10
2022
|
Kevin D. Bunker Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
10,000
-2.13%
|
$470,000
$47.13 P/Share
|
|
Mar 07
2022
|
Cam Gallagher President, Interim CFO |
SELL
Open market or private sale
|
Direct |
10,000
-1.3%
|
$450,000
$45.23 P/Share
|
|
Mar 02
2022
|
Anthony Y Sun President & CEO |
SELL
Open market or private sale
|
Direct |
10,471
-0.43%
|
$523,550
$50.51 P/Share
|
|
Mar 01
2022
|
Anthony Y Sun President & CEO |
SELL
Open market or private sale
|
Direct |
10,471
-0.43%
|
$513,079
$49.9 P/Share
|
|
Feb 23
2022
|
Epperly Melissa B, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,913
-0.36%
|
$93,737
$49.2 P/Share
|
|
Feb 22
2022
|
Kevin D. Bunker Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
10,000
-1.49%
|
$490,000
$49.09 P/Share
|
|
Feb 15
2022
|
Cam Gallagher President, Interim CFO |
SELL
Open market or private sale
|
Direct |
10,000
-0.85%
|
$520,000
$52.04 P/Share
|
|
Feb 14
2022
|
Anthony Y Sun President & CEO |
SELL
Open market or private sale
|
Direct |
4,733
-0.19%
|
$236,650
$50.46 P/Share
|
|
Feb 14
2022
|
Cam Gallagher President, Interim CFO |
SELL
Open market or private sale
|
Direct |
7,188
-0.6%
|
$359,400
$50.36 P/Share
|
|
Feb 14
2022
|
Alexis Pinto Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
691
-1.51%
|
$34,550
$50.46 P/Share
|
|
Feb 14
2022
|
Dimitris Voliotis SVP, Clinical Development |
SELL
Open market or private sale
|
Direct |
601
-1.82%
|
$30,050
$50.46 P/Share
|
|
Feb 14
2022
|
Kevin D. Bunker Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,688
-0.2%
|
$234,400
$50.4 P/Share
|
|
Feb 10
2022
|
Anthony Y Sun President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
50,431
+3.96%
|
-
|
|
Feb 10
2022
|
Cam Gallagher President, Interim CFO |
BUY
Grant, award, or other acquisition
|
Direct |
15,798
+1.94%
|
-
|
|
Feb 10
2022
|
Epperly Melissa B, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,405
+5.8%
|
-
|
|
Feb 10
2022
|
Alexis Pinto Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,405
+41.7%
|
-
|
|
Feb 10
2022
|
Dimitris Voliotis SVP, Clinical Development |
BUY
Grant, award, or other acquisition
|
Direct |
10,329
+38.39%
|
-
|
|
Feb 10
2022
|
Kevin D. Bunker Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
10,000
-1.42%
|
$530,000
$53.63 P/Share
|
|
Feb 10
2022
|
Kevin D. Bunker Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,481
+2.84%
|
-
|
|
Feb 07
2022
|
Cam Gallagher President, Interim CFO |
SELL
Open market or private sale
|
Direct |
10,000
-0.84%
|
$530,000
$53.54 P/Share
|
|
Feb 02
2022
|
Anthony Y Sun President & CEO |
SELL
Open market or private sale
|
Direct |
10,471
-0.44%
|
$607,318
$58.08 P/Share
|
|
Feb 01
2022
|
Anthony Y Sun President & CEO |
SELL
Open market or private sale
|
Direct |
10,471
-0.22%
|
$607,318
$58.09 P/Share
|
|
Jan 20
2022
|
Kevin D. Bunker Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
10,000
-1.78%
|
$600,000
$60.22 P/Share
|
|
Jan 20
2022
|
Dimitris Voliotis SVP, Clinical Development |
SELL
Open market or private sale
|
Direct |
10,000
-36.15%
|
$600,000
$60.87 P/Share
|
|
Jan 20
2022
|
Dimitris Voliotis SVP, Clinical Development |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+38.1%
|
$180,000
$18.0 P/Share
|
|
Jan 19
2022
|
Dimitris Voliotis SVP, Clinical Development |
SELL
Open market or private sale
|
Direct |
10,000
-25.1%
|
$610,000
$61.43 P/Share
|
|
Jan 19
2022
|
Dimitris Voliotis SVP, Clinical Development |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+38.1%
|
$180,000
$18.0 P/Share
|
|
Jan 18
2022
|
Dimitris Voliotis SVP, Clinical Development |
SELL
Open market or private sale
|
Direct |
10,000
-21.19%
|
$630,000
$63.05 P/Share
|
|
Jan 18
2022
|
Dimitris Voliotis SVP, Clinical Development |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+38.1%
|
$180,000
$18.0 P/Share
|
|
Jan 18
2022
|
Cam Gallagher President, Interim CFO |
SELL
Open market or private sale
|
Direct |
10,000
-0.62%
|
$630,000
$63.05 P/Share
|
|
Jan 10
2022
|
Kevin D. Bunker Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
10,000
-1.27%
|
$680,000
$68.58 P/Share
|
|
Jan 05
2022
|
Cam Gallagher President, Interim CFO |
SELL
Open market or private sale
|
Direct |
10,000
-0.35%
|
$760,000
$76.07 P/Share
|
|
Jan 04
2022
|
Anthony Y Sun President & CEO |
SELL
Open market or private sale
|
Direct |
10,471
-0.22%
|
$827,209
$79.11 P/Share
|
|
Jan 03
2022
|
Kimberly Blackwell Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,000
-16.67%
|
$83,000
$83.74 P/Share
|
|
Jan 03
2022
|
Kimberly Blackwell Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+14.29%
|
$47,000
$47.8 P/Share
|
|
Jan 03
2022
|
Anthony Y Sun President & CEO |
SELL
Open market or private sale
|
Direct |
10,471
-0.14%
|
$837,680
$80.84 P/Share
|